Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$6.10 USD
+0.11 (1.84%)
Updated May 28, 2024 04:00 PM ET
After-Market: $6.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CAPR 6.10 +0.11(1.84%)
Will CAPR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CAPR
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
Other News for CAPR
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform
Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers
Capricor Therapeutics initiated with bullish view at Oppenheimer, here's why
Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments